What is on the horizon for the management of osteosarcoma?
2021 ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guidelines open the door to genetic testing but the search for new treatments continues
Is there a future for immunotherapy in sarcoma?
Continued efforts in patient selection, combination strategies and novel approaches may help to turn the tide for immunotherapeutics in sarcoma, according to Prof. Jean-Yves Blay
Single-agent doxorubicin – is it still the standard first-line therapy for all soft tissue sarcoma subtypes?
In practice, doxorubicin alone is often not used as the first-line standard of care for soft tissue sarcomas; however, a lack of high-quality survival data precludes other regimens becoming the gold standard
Patient sex and gut microbiome play a role in modulating response to immunotherapy
Research is ongoing to investigate influencing factors of immune checkpoint inhibition, encouraging a more holistic understanding of individual characteristics to improve clinical outcomes
Cancer Research
Food for thought: dietary effects on tumour metabolism and progression
Thanks to our deeper understanding of the underlying biology and molecular mechanisms that govern cancer, we are gaining important ground in tackling the myriad mediators of this disease.
Cancer Control Principles
Fair pricing in an unfair world — where is the value?
People think cancer care is unaffordable because of the high prices of cancer medicines. Some state that innovations in oncology mostly happen thanks to massive investments in the private sector.
What do non-oncologists know about cancer care?
A survey reveals that physicians outside the field of oncology are insufficiently updated on the latest advances in cancer care, thus increasing the risk of providing misleading information and inadequate support to patients.
Optimising clinical trials for greater inclusiveness
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.
Quality cancer care starts with training oncologists at the highest standards
Despite the encouraging findings of a new global survey demonstrating a high rate of uptake of the ESMO/ASCO Global Curriculum in Medical Oncology, resource limitations in lower-income regions as well as country-specific political circumstances may be hindering its implementation locally.
Anti-cancer medicines are typically approved in the USA eight months before Europe
Discrepancies in anti-cancer drug approvals around the globe are even bigger in low- and middle-income countries, raising some questions about how they impact on patients’ access to quality cancer care.